Baltimore, Maryland-based WellDoc has raised $22 million in a round. Samsung Ventures acted as the lead investor in the round with existing investor Merck Global Health Innovation Fund serving as co-lead. Adage Capital Management, Excel Venture Management, Alexandria Venture Investments and Hudson River Capital Partners LLC also participated.
WellDoc is disrupting healthcare using mobile technology to transform the treatment of chronic disease. Their product BlueStar is the first mobile prescription therapy developed for adults living with type 2 diabetes and their doctors.
BlueStar helps adults living with type 2 diabetes and their doctors to improve self-management and help decrease A1C. BlueStar analyzes diabetes data entered by the patient, including blood glucose and medications. BlueStar compares past data trends to deliver personalized, contextualized guidance in-the-moment. BlueStar delivers summarized, curated data and analytics to the healthcare team to improve decisions and drive efficacy.